Table 2. Treatment history.
| No. of patients (n=79) | % | |
|---|---|---|
| Surgery | 79 | 100.0 |
| Adjuvant radiation therapy | 58 | 73.4 |
| Hormonal therapya | 68 | 86.0 |
| Previous adjuvant chemotherapy | 44 | 55.6 |
| Previous chemotherapy for MBC | ||
| 1 regimen | 30 | 37.9 |
| 2 regimens | 23 | 29.1 |
| ⩾3 regimens | 26 | 32.9 |
| Previous anthracycline-based chemotherapy | 79 | 100.0 |
| Adjuvant only | 18 | 22.8 |
| Metastatic only | 54 | 68.4 |
| Both settings | 7 | 8.9 |
| Anthracycline-free interval (months) | ||
| 0–12 | 33 | 41.8 |
| >12 | 46 | 58.2 |
| Dose of previous anthracycline-based chemotherapy b | ||
| Epirubicin (median, 360 mg m−2; range 140–810) | 56 | 70.9 |
| Mitoxantrone (median, 90 mg m−2; range 12–132) | 11 | 13.9 |
| Doxorubicin (median, 300 mg m−2; range 105–400) | 8 | 10.1 |
| Previous taxane-based chemotherapy | 54 | 68.4 |
| Adjuvant only | 3 | 5.6c |
| Metastatic only | 51 | 94.4c |
| Both settings | 0 | 0 |
| Taxane-free interval (months) | ||
| 0–12 | 39 | 72.2c |
| >12 | 15 | 27.8c |
MBC=metastatic breast cancer.
a
Adjuvant and/or metastatic.
b
Six patients received an unknown cumulative dose of anthracyclines; two patients received epirubicin and mitoxantrone.
c
In percentage of taxane-pretreated patients, n=54.